Suggested remit: To appraise the clinical and cost effectiveness of mirvetuximab soravtansine within its marketing authorisation for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6442
Provisional Schedule
- Committee meeting:
- 04 November 2025
- Expected publication:
- 28 January 2026
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- AbbVie (Mirvetuximab soravtansine)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Ovacome
- Ovarian Cancer Action
- Target Ovarian Cancer
- Professional groups
- Association of Cancer Physicians
- Association of Cancer Physicians British Gynaecological Cancer Society (BGCS)
- Cancer Research UK
- Royal College of Physicians
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 March 2025 | The company have asked NICE to delay this appraisal so that they can incorporate additional data into their submission. NICE have agreed to this request. This appraisal will now be considered by the NICE Technology Appraisal Committee at a meeting on 4 November 2025 |
| 09 January 2025 | Invitation to participate |
| 05 November 2024 - 03 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6442 |
| 05 November 2024 | In progress. Scoping commencing |
| 22 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual